Apellis Pharmaceuticals, Inc.APLSNASDAQ
Loading
Price to Sales: Discounted ValuationCompressed
Percentile Rank58
3Y CAGR-64.9%
5Y CAGR-28.7%
Studio
Year-over-Year Change

Price-to-sales ratio

3Y CAGR
-64.9%/yr
Annual compound
5Y CAGR
-28.7%/yr
Recent deceleration
Percentile
P58
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
3 yr
Consecutive declineCompressed
PeriodValueYoY Change
20253.15-37.7%
20245.06-71.8%
202317.91-75.4%
202272.75+21.3%
202159.96+249.6%
202017.15-
20190.00-
20180.00-
20170.00-
20160.00-